Onclive Team

Patients with untreated extensive-stage small cell lung cancer had statistically significant improvement in overall survival when the PD-L1 inhibitor durvalumab (Imfinzi) was added to chemotherapy.

Findings from a small case series of patients with lung cancer added to evidence that afatinib is a potentially effective treatment in patients with lung adenocarcinoma who have NRG1 fusions.

The first-in-class AXL inhibitor bemcentinib (BGB324) demonstrated activity in combination with the PD-1 inhibitor pembrolizumab in patients with advanced non–small cell lung cancer who had no prior exposure to immunotherapy.

The investigational KRAS inhibitor AMG 510 induced near-universal disease control in patients with advanced non–small cell lung cancer with KRAS mutations.

We traveled to New York City, New York, for a State of the Science Summit™ on Multiple Myeloma, which featured insights from the faculty from the Mount Sinai Hospital.

We traveled to Boston, Massachusetts, for a State of the Science Summit™ on Genitourinary Cancers, which featured insights from the faculty from the Dana-Farber Cancer Institute.

The group of researchers is conducting the largest African-American prostate cancer study ever, aiming to include 10,000 men nationwide.

Dr. Andrew Fabiano included in Spine Society's 20 Under 40, also named an ABNS guest examiner.

Baylor College of Medicine has been awarded more than $17.4 million by the Cancer Prevention & Research Institute of Texas to support new cancer research and programs, core facilities and recruitment of new faculty.

The Gayle and Tom Benson Cancer Center at Ochsner Medical Center (Benson Cancer Center) has again been granted Three-Year Accreditation with Commendation from The Commission on Cancer, a quality program of the American College of Surgeons.

We traveled to Milwaukee, Wisconsin, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from the faculty from the Medical College of Wisconsin.

Stephen V. Liu, MD, of Medstar Georgetown University Medical Center, and Konstantinos Arnaoutakis, MD, of Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences, discuss the results of a Twitter poll regarding the use of single-agent immunotherapy versus combination chemotherapy and immunotherapy in a patient with nonsquamous non–small cell lung cancer and to shed light on the data that support each intended treatment choice.

Saul Priceman, PhD, City of Hope assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation, and his research team have received a $9.28 million award from the California Institute for Regenerative Medicine to support a chimeric antigen receptor T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.

Noopur Raje, MD, highlights the multitude of available and emerging options in relapsed myeloma, as well as the key factors for treatment selection in this heterogeneous population.

We traveled to Lexington, Kentucky, for a State of the Science Summit™ on Neuroendocrine Tumors, which featured insights from the faculty from University of Kentucky Markey Cancer Center.

The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute announced formation of the Pelotonia Institute for Immuno-Oncology, a comprehensive bench-to-bedside research initiative focused on harnessing the body’s immune system to fight cancer at all levels—from prevention to treatment and survivorship.

Physicians at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis have been awarded a $7.8 million grant from the National Cancer Institute to play a leading role in designing, conducting and enrolling patients in clinical trials through the NCI

We traveled to Pasadena, California, for a State of the Science Summit™ on Breast Cancer, which featured insights from the faculty from City of Hope.

With its long-standing commitment to patients, the designation makes City of Hope the highest ranked cancer hospital in the West.

Sylvester Comprehensive Cancer Center, part of the University of Miami Leonard M. Miller School of Medicine, has received the prestigious NCI designation from the National Cancer Institute.

Financial pledge from Pelotonia represents one of the largest gifts ever to The Ohio State University and honors the 2,265 riders who participated in the inaugural ride in 2009.

PD-L1–positive natural killer cells may prove to be another important immune effector cell for checkpoint inhibitor-based cancer immunotherapy.

Patrick I. Borgen, MD, of Maimonides Medical Center, shares his live-by mottos as a breast cancer surgeon, a patient who defined his career, and what fuels his passion to fight breast cancer and remove opioid use after surgery.

A new molecular mechanism discovered by UT Southwestern researchers indicates that drugs currently used to treat less than 10 percent of breast cancer patients could have broader effectiveness in treating all cancers where the drugs are used, including ovarian and prostate cancers.

The growth and aging of the population combined with advances in the early detection and treatment of cancer have resulted in a growing population of survivors across the nation, according to a study from the American Cancer Society and the National Cancer Institute.

We traveled to Dallas, Texas, for a State of the Science Summit™ on Non–Small Cell Lung Cancer, which featured insights from Baylor Scott and White Health System faculty.

Gary J. Schiller, MD, discusses the challenges with treating patients with hairy cell leukemia and some emerging therapies that could impact clinical practice.

We traveled to Tampa, Florida, for a State of the Science Summit™ on Gastrointestinal Malignancies, which featured insights from the faculty from Moffitt Cancer Center and Mayo Clinic.

After decades of quiescence, the therapeutic landscape of hairy cell leukemia is undergoing rapid evolution.

Despite the significant progress that has been made regarding the incidence, risk factors, and symptoms of hairy cell leukemia, diagnosis remains a challenge, due in part to the low incidence of the disease.